Markus Hecker
Corporate Officer/Principal bei Ruprecht-Karls-Universität Heidelberg
Profil
Markus Hecker is the founder of Avontec GmbH, which was founded in 2001.
He held the title of Director-Supervisory Board from 2009 to 2010.
Dr. Hecker is currently working at Ruprecht-Karls-Universität Heidelberg as Director-Physiology & Pathophysiology since 2009.
Dr. Hecker has previously worked at the University of Freiburg, St. Bartholomew's Hospital, and Georgetown University as a Principal.
From 1996 to 2004, he worked at the University of Gottingen as a Principal.
Dr. Hecker obtained his doctorate degree from Universität Konstanz.
Aktive Positionen von Markus Hecker
Unternehmen | Position | Beginn |
---|---|---|
Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 05.11.2009 |
Ehemalige bekannte Positionen von Markus Hecker
Unternehmen | Position | Ende |
---|---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Gründer | 16.06.2010 |
University of Gottingen | Corporate Officer/Principal | 01.01.2004 |
University of Freiburg | Corporate Officer/Principal | - |
St. Bartholomew's Hospital | Corporate Officer/Principal | - |
Georgetown University | Corporate Officer/Principal | - |
Ausbildung von Markus Hecker
Universität Konstanz | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
St. Bartholomew's Hospital |